Common multi-allelic copy-number variants (CNVs) appear enriched for phenotypic associations compared to their di-allelic counterparts^[@R1]-[@R4]^. Here we investigated the influence of gene-dosage effects on adiposity through a CNV association study of gene expression levels in adipose tissue. We identified significant association of a multi-allelic CNV encompassing the salivary amylase gene (*AMY1*) with body mass index and obesity, and replicated this finding in 6,200 subjects. Increased *AMY1* copy-number was positively associated with both amylase gene expression (*P*=2.31×10^−14^) and serum enzyme levels (*P*\<2.20×10^−16^), while reduced *AMY1* copy-number was associated with increased BMI (per-estimated-copy:*β*=−0.15\[0.02\]kg/m^2^;*P*=6.93×10^−10^) and obesity risk (per-estimated-copy:OR=1.19\[1.13-1.26\]~95%CI~;*P*=1.46×10^−10^). The OR of 1.19 per-copy of *AMY1* translates to about an eight-fold difference in risk of obesity between subjects in the top (CN\>9) and bottom (CN\<4) 10% of the copy-number distribution. Our study provides a first genetic link between carbohydrate metabolism and BMI and demonstrates the power of integrated genomic approaches beyond genome-wide association studies.

We designed a gene-centric association study (GCAS) to identify common CNVs overlapping genes and inducing a dosage effect on gene expression, hypothesising that these might be enriched for physiologically-relevant CNVs. To achieve this, we conducted a family-based association analysis of signal intensity data from DNA arrays (log R ratio and B-allele frequency) with transcriptomic data from adipose tissue using famCNV^[@R5]^ in 149 Swedish families ascertained through siblings discordant for obesity^[@R6]^ ([Table 1](#T1){ref-type="table"};[Figure 1](#F1){ref-type="fig"};[Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). A total of 76 probes located within putative CNVs showed a dosage effect on gene expression at 1% FDR ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Of these probes, only cnvi0020639, located within a CNV overlapping the amylase gene cluster (including the *AMY1* salivary and the *AMY2* pancreatic amylase genes expression probeset 208498_s\_at; FDR=6.88**×**10^−3^), was also associated with adiposity \[both BMI (*P*=3.86**×**10^−4^) and fat mass (*P*=3.11**×**10^−4^)\] ([Supplementary Figures 2-4](#SD1){ref-type="supplementary-material"}). Reduced signal intensity at this probe was associated with increased adiposity levels ([Table 2](#T2){ref-type="table"};[Figure 2](#F2){ref-type="fig"};[Supplementary Figures 2-4](#SD1){ref-type="supplementary-material"}).

This inverse association between copy-number in the amylase region and BMI was first replicated using signal intensity data from DNA arrays in 972 subjects from TwinsUK ([Table 1](#T1){ref-type="table"})^[@R7]^. The strongest association was observed at cnvi0022844 (*P*=1.13×10^−3^;[Table 2](#T2){ref-type="table"}), which showed significant association with BMI after Bonferroni correction. When multiple probes were considered through principal component analysis, the BMI association signal actually extended over a region between cnvi0022844 and cnvi0016754 (*P*=1.32×10^−3^), which overlapped the cnvi0020639 probe associated with adiposity in the Swedish discovery families. These results, although supportive of the association in the amylase region, did not permit us to distinguish which of the salivary or pancreatic amylases was driving the association with adiposity, necessitating use of a non-array-based method of copy-number measurement.

Consequently, we estimated copy-number at *AMY1* and *AMY2* in 481 subjects from the Swedish families ([Table 1](#T1){ref-type="table"}) using quantitative real-time PCR (qPCR). This approach generates a continuous intensity distribution from which integer copy-numbers can be inferred by comparison to a reference sample of known copy-number ([Supplementary Information](#SD1){ref-type="supplementary-material"}). Given the many technical challenges inherent in copy-number measurement at multi-allelic loci^[@R2],[@R8]-[@R11]^, we treated these discretised measurements as relative estimates or surrogates correlated with the true underlying copy-number state, as opposed to absolute copy-number genotypes.

Only three estimated copy-number states (one to three) were detected for the pancreatic amylase (*AMY2*) gene, and these were not associated with either BMI or fat mass ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). In contrast, copy-number estimates at *AMY1* ranged from two to fourteen, and showed association with both BMI (*P*=8.08**×**10^−3^) and fat mass (*P*=8.53**×**10^−3^) confirming our previous DNA-array based analysis ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). We found greater correlation between signal intensity at cnvi0020639 and *AMY1* (*r*=0.73; *P*\<2.20**×**10^−16^) than *AMY2* copy-number (*r*=0.35; *P*=1.25**×**10^−8^), suggesting that the GCAS association was mainly capturing copy-number variation at *AMY1* as opposed to *AMY2*, justifying follow-up of the former. Furthermore, we validated accuracy of the *AMY1* qPCR assay by using *AMY1* copy-number estimates derived using whole-genome shotgun-sequencing data from the 1000 Genomes Project^[@R12]^, and observed a correlation of 0.94 (*P*\<2.20**×**10^−16^) between *AMY1* copy-number estimates derived by qPCR and sequencing ([Supplementary Figures 5-8](#SD1){ref-type="supplementary-material"}; [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). To further validate the *AMY1* qPCR assay, we also compared the copy-number measured by qPCR in 96 samples from the DESIR cohort^[@R13]^ with *AMY1* copy-number measured by digital PCR in the same samples, obtaining high correlation between the two methods (*r*=0.95; *P*\<2.20**×**10^−16^; [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}). Analogously, high correlation (*r*=0.98; *P*\<2.20**×**10^−16^; [Supplementary Figure 9](#SD1){ref-type="supplementary-material"}) was also observed between copy-numbers measured using the qPCR assay used in this study and those obtained using a different qPCR assay on the same 96 DESIR samples.

To replicate the observed association in a larger sample, we next estimated *AMY1* copy-number by qPCR in an additional sample of 1,479 female subjects from TwinsUK^[@R14]^ and 2,137 male and female subjects from DESIR^[@R13]^ ([Table 1](#T1){ref-type="table"}). The two population samples showed a similar copy-number distribution (Wilcoxon test *P*\>0.05) with estimated median copy-number of six, ranging from one to eighteen ([Supplementary Figure 10](#SD1){ref-type="supplementary-material"}; [Supplementary Tables 4-5](#SD1){ref-type="supplementary-material"}). Meta-analysis of *AMY1* effects in TwinsUK and DESIR (total *n*=3,616) showed significant association between reduced *AMY1* copy-number and increased BMI (per copy-number *β*=−0.15\[0.02\]kg/m^2^;*P*=6.93×10^−10^; [Table 2](#T2){ref-type="table"};[Figure 3](#F3){ref-type="fig"};[Supplementary Tables 6-9](#SD1){ref-type="supplementary-material"}). Results of associations assessed using both the qPCR intensity signal as a continuous measure, as well as discretised using an unsupervised clustering approach (k-means), were concordant with those generated using integer copy-numbers ([Supplementary Information](#SD1){ref-type="supplementary-material"}).

We then assessed the effect of *AMY1* copy-number on obesity susceptibility by selecting obese cases (BMI≥30kg/m^2^) and normal-weight controls (BMI\<25kg/m^2^) from TwinsUK and DESIR and by measuring *AMY1* copy-number by qPCR in an additional 205 severely obese cases and 358 age-matched controls from the AOB^[@R15]^ study ([Table 1](#T1){ref-type="table"};[Supplementary Information](#SD1){ref-type="supplementary-material"}). In these European samples, subjects with lower estimated *AMY1* copy-number showed significantly increased risk of obesity in each of the three samples (per-estimated *AMY1* copy-number meta-analysis: OR=1.19\[1.13-1.26\]~95%CI~;*P*=1.46×10^−10^;[Table 2](#T2){ref-type="table"};[Figure 3](#F3){ref-type="fig"}). The *AMY1* copy number distribution in our sample ranged from one to eighteen copies, with approximately 10% of subjects carrying fewer than four copies of *AMY1*, and 10% of subjects with an *AMY1* copy number greater than nine ([Table 2](#T2){ref-type="table"}). Given the multi-allelic nature of the *AMY1* CNV, this OR of 1.19 per copy of *AMY1* translates to about an eight-fold difference in risk of obesity between subjects in the top (CN\>9) and bottom (CN\<4) decile of the estimated *AMY1* copy-number distribution (OR=7.67\[3.92-14.99\]~95%CI~;*P*=2.52×10^−9^;[Supplementary Table 10](#SD1){ref-type="supplementary-material"}). Using a multi-factorial liability threshold model^[@R16]^, we estimated the proportion of total variance of obesity explained by estimated *AMY1* copy-number to lie between 1.73-7.94%\[95%CI\] ([Supplementary Table 11](#SD1){ref-type="supplementary-material"}). Therefore, based on an estimated heritability of 40-70%^[@R17],[@R18]^, copy-number variation at *AMY1* may account for 2.47-19.86% of the total genetic variation of obesity. Analogously, we estimated that between 0.66% and 4.40% of the proportion of genetic variance of BMI could be explained by inferred *AMY1* copy-number in these European samples.

As all the samples included in our analyses were of European origin, we reasoned that replication in a sample of different ethnicity and under differing environmental influences on obesity would provide greater support for its physiological role. We therefore selected a Singaporean Chinese case-control sample from SP2^[@R19]^. A total of 136 obese and 197 overweight subjects were identified among the 2,431 Chinese subjects included in the SP2 cohort, with 325 matched lean Chinese SP2 normal-weight controls. *AMY1* copy-number was measured by qPCR in all 658 subjects. Median copy-number in SP2 normal-weight subjects was 6 (ranging from 2 to 16), similar to our French DESIR and UK TwinsUK populations, and in line with previous observations by Perry *et al*^[@R20]^. Case-control association analysis in the Chinese sample showed reduced *AMY1* estimated copy number to be associated with increased risk of obesity (per copy-number OR=1.17\[1.05-1.29\]~95%CI~;*P*=3.73×10^−3^). Extending the case sample to include the 197 overweight subjects further confirmed the results (per copy-number OR=1.13\[1.06-1.21\]~95%CI~;*P*=3.52×10^−4^).

To validate our *AMY1* genomic copy-number data at the protein level, we investigated the effect of copy-number variation at *AMY1* and *AMY2* on serum amylase enzyme levels, and their relationship with BMI using 468 French morbidly obese subjects from the ABOS study ([Table 1](#T1){ref-type="table"};[Supplementary Table 12](#SD1){ref-type="supplementary-material"}). On average, salivary and pancreatic amylase proportions were approximately equal in serum (52% and 48%, respectively) and their levels showed close positive association with copy-number variation at their respective genes (*P*\<2.20**×**10^−16^ and *P*=1.04**×**10^−11^, respectively; [Supplementary Figure 11](#SD1){ref-type="supplementary-material"}). BMI was inversely associated with serum salivary amylase (*β*=−0.23\[0.04\]kg/m^2^;*P*=2.26**×**10^−7^;[Supplementary Figure 12](#SD1){ref-type="supplementary-material"}) and to a lesser extent serum pancreatic amylase (*β*=−0.23\[0.06\]kg/m^2^;*P*=2.29**×**10^−4^;[Supplementary Figure 12](#SD1){ref-type="supplementary-material"}), likely reflecting the physiological correlation between the levels of the two enzymes (*r*=0.21;*P*=4.29**×**10^−6^).

Salivary amylase catalyses hydrolysis of the α-1,4-glycosidic bonds of starch, initiating carbohydrate digestion in the oral cavity. While individual salivary amylase levels vary in response to environmental factors including psychological stress^[@R21]^, they are genetically influenced by and directly correlated with the highly variable copy-number at *AMY1*^[@R20],[@R22]^. Increased gene copy-numbers at this locus are believed to have evolved in the human lineage as a consequence of a shift to a starch-rich diet^[@R23]^. Human populations traditionally consuming a high proportion of carbohydrates in their diet show higher copy-numbers and salivary amylase activity than those consuming a low-starch diet^[@R20],[@R24]^. Both the salivary glands and pancreas contribute similarly to determine overall levels of serum amylase^[@R25]^, although enzyme activity is also detectable in other organs, including adipose tissue^[@R26],[@R27]^. Indeed amylase was among the 30% most-highly expressed genes in adipose tissue in both our discovery sample and publicly-available data from the general population, thus suggesting that this gene is actively expressed in adipose tissue ([Supplementary Information](#SD1){ref-type="supplementary-material"}). Whether adipose tissue is functionally involved in the link between *AMY1* copy-number and obesity, or whether this link implicates a different tissue in which *AMY1* is also actively transcribed warrants further investigation.

Decreased blood amylase levels have been observed in both obese humans^[@R28]^ and rats^[@R29]^, and have recently been associated with increased risk of metabolic abnormalities^[@R30],[@R31]^ and reduced pre-absorptive insulin release^[@R32]^. Furthermore, a recent study in mice fed a high fat/high sugar diet suggested association between the amylase locus and weight gain^[@R33]^. In these mice, this locus was also shown to be associated with the proportion of *Enterobacteriaceae* in the gut microbiota^[@R33]^, which have been previously correlated with obesity in humans^[@R34]^.

Rare copy-number variants have recently been implicated in highly-penetrant forms of obesity^[@R35],[@R36]^ and severe thinness^[@R37]^, through a gene dosage effect. Common bi-allelic CNVs have also been associated with BMI^[@R38]-[@R41]^, however, since most of these are reliably tagged by surrounding SNPs^[@R42]^, they share the same properties of small effect sizes and limited predictive value for obesity risk. In contrast, complex multi-allelic CNVs show decreased linkage disequilibrium with surrounding SNPs ([Supplementary Table 13](#SD1){ref-type="supplementary-material"}) and are consequently less detectable by SNP-based GWAS^[@R43]^. Surprisingly, *FTO* is the most-replicated obesity susceptibility gene identified through GWAS^[@R41]^, yet in our analyses estimated *AMY1* copy-number appeared to show stronger association with BMI than *FTO* SNPs ([Supplementary Tables 14-15](#SD1){ref-type="supplementary-material"}). It is conceivable that high structural variability in the amylase region and subsequent low SNP coverage ([Supplementary Figures 13-14](#SD1){ref-type="supplementary-material"}) may have hampered previous SNP-based GWAS attempts to detect association between the amylase cluster and adiposity. Indeed, examination of data from the most recent BMI meta-analysis conducted by the GIANT consortium^[@R41]^ revealed a large gap in SNP coverage across the locus encompassing the salivary amylase gene ([Supplementary Figure 14](#SD1){ref-type="supplementary-material"}).

Present DNA high-throughput methods for CNV assessment, including array-, PCR- and sequencing-based approaches, are all affected by a wide number of variables including DNA source, extraction methods, quality and concentration, as well as experimental factors inducing batch effects^[@R10],[@R11],[@R44]^. These factors complicate copy-number measurement at multi-allelic CNVs and hinder pooling of data from multiple centres. The observed association of *AMY1* with obesity may rekindle interest in the role of multi-allelic CNVs in common disease, driving development of novel technological approaches for accurate and high-throughput measurement of absolute copy-number at such loci. These technological improvements will enable high-quality association analyses at such loci in larger sample sizes similar to those included in SNP association studies, and are mandatory for disease risk-assessment at the individual level, paving the way towards personalized medicine.

Our study provides a first genetic link between carbohydrate metabolism and obesity, with low copy-number at *AMY1* resulting in decreased salivary amylase levels and a higher risk of obesity. This finding provides intriguing insight into some of the biological mechanisms underlying obesity, as well as a novel rationale for the investigation of innovative obesity treatments based on manipulation of digestive enzyme levels.

ONLINE METHODS {#S1}
==============

Further detailed methods are provided in the [Supplementary Information](#SD1){ref-type="supplementary-material"}. Associations were assessed using linear mixed effects models, including plate as a random effect and family structure as an additional random effect where appropriate. Age and sex were included as covariates.

Discovery {#S2}
---------

The discovery sample included 149 Swedish families (342 subjects) ascertained through an obesity-discordant sib-pair (BMI difference\>10kg/m^2^)^[@R6]^. Gene expression for 29,546 transcripts (16,563 Ensembl genes) was measured in subcutaneous adipose tissue using the Affymetrix Human Genome U133 Plus 2.0 microarray. GWAS signal intensity data from Illumina 610K-Quad arrays were available for 348,150 probes lying within each transcript plus 30kb upstream and downstream to encompass the coding regions and their internal and nearby regulatory regions.

Quantitative real-time PCR (qPCR) was carried out to infer relative copy-number measurements reflecting the underlying copy-number distribution at *AMY1* and *AMY2*, respectively, using the TaqMan assays Hs07226362_cn and Hs04204136_cn on an Applied Biosystems 7900HT Real-Time PCR System. Association analyses were carried out for 481 subjects with complete data on BMI and dual-energy X-ray absorptiometry (DEXA)-derived fat mass.

Replication {#S3}
-----------

*In-silico* replication of the BMI association was conducted using 972 female subjects from the UK adult twin registry (TwinsUK) cohort^[@R14]^ using intensity signals from Illumina 610K-Quad arrays^[@R7]^. Association with BMI and obesity was analysed in two population samples using qPCR estimates of *AMY1* copy-number for 1,479 female twins from TwinsUK^[@R14]^ and 2,137 subjects from the French Data from the Epidemiological Study on the Insulin Resistance syndrome (DESIR)^[@R13]^ cohort. Obesity association with qPCR data was also assessed in an additional case-control sample of 205 obese cases and 358 age-matched controls from the French Adult Obesity study (AOB)^[@R15]^. An additional case-control sample was extracted from the Singapore Prospective Study Program (SP2) cohort, a population-based study including 2,431 adult Chinese Singaporean subjects^[@R19]^. Obesity in the Chinese population was defined as BMI≥28kg/m^2^ and normal-weight as BMI\<23kg/m^2^, based on criteria set by the Working Group on Obesity in China^[@R45]^ and the WHO expert consultation for Asia^[@R46]^. Accordingly, a total of 136 obese and 197 overweight subjects were identified among the 2,431 Chinese subjects of the SP2 cohort, with 325 matched lean SP2 subjects selected as normal-weight controls.

In order to avoid any potential population stratification impacting on our association analyses resulting from the known differences in *AMY1* copy number distribution between populations traditionally consuming high *versus* low starch diets^[@R20]^, we carried out genotype principal component analysis using genome-wide SNP array data to ensure that samples included in each analysis were of the same ethnicity and genetic background. Furthermore, *AMY1* association analyses were conducted separately in each of the study populations and then combined by meta-analysis using METAL^[@R47]^ rather than pooling.

Protein levels {#S4}
--------------

'*Atlas Biologique de l'Obésité Sévère*' (ABOS) is a French cohort comprised of candidates for bariatric surgery. Serum pancreatic and total amylase levels for 468 patients were measured by an enzymatic colorimetric assay with an autoanalyzer (CoBAS Icobas® 8000 modular analyser series; kits AMYL2-03183742122 and AMY-P-20766623322, Hoffman-La Roche Ltd). Serum salivary amylase levels were calculated by subtracting serum pancreatic amylase levels from total serum amylase levels.
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![Manhattan plot of gene-centric CNV association study (GCAS) results with gene expression levels in subcutaneous adipose tissue from the Swedish sib-pair dataset\
Chromosomal location for each probe is given on the horizontal axis for each of the 22 autosomes, while minus log~10~ (*P*) of the association between probe signal intensity and gene expression levels is shown on the vertical axis. The probes tested against the amylase genes transcriptional levels are shown in green.](emss-57335-f0001){#F1}

![The amylase region in detail\
Top to bottom: famCNV association results between signal intensity at probes within 30kb of the amylase cluster and amylase expression levels (probeset 208498_s\_at) in adipose tissue (black dots) in the Swedish family discovery study, with chromosomal coordinates given on the horizontal axis and minus log~10~(*P*) on the vertical axis; locations of probes showing association between signal intensity and BMI: cnvi0020639 (blue; Swedish family discovery study), cnvi0022844 (red; TwinsUK); gene content in the amylase region based on the human reference sequence (hg19; RefSeq), depicting *AMY2B, AMY2A* and the *AMY1A/B/C* genes, as well as two high sequence similarity segmental duplications in the region; LD between HapMap markers (release 23) calculated with HaploView^[@R46]^ (darker shading corresponds to higher r^2^ value). Because of the repetitive nature of this region, which contains six paralogs (including one pseudogenized copy) in the reference genome ([Supplementary Figure 13](#SD1){ref-type="supplementary-material"}), the cnvi0020639 and the cnvi0022844 probes were found to map to two locations within the amylase gene cluster.](emss-57335-f0002){#F2}

![Effect of estimated *AMY1* copy-number on obesity and BMI. A: Scatter plots of raw qPCR signal intensity (ΔΔCt) plotted against BMI for the TwinsUK and DESIR samples. B: Boxplots of ΔΔCt in normal weight (BMI\<25kg/m^2^) and obese (BMI≥30kg/m^2^) subjects in the TwinsUK, DESIR and AOB samples. For plots A and B, low ΔΔCt values correspond to high *AMY1* copy-numbers. C: relative copy-number distribution in obese cases (BMI≥30 kg/m^2^; black bars) versus normal weight controls (BMI\<25 kg/m^2^; grey bars) in the TwinsUK, DESIR, and AOB studies. Estimated copy-numbers higher than 13 (showing frequency \< 2.5%) were collapsed together into a single category. D and E: BMI at different estimated *AMY1* copy-numbers and *AMY1* copy-number estimates by BMI categories in the TwinsUK and DESIR population samples. WHO BMI classification: Underweight (\<18.5); Normal range (18.50 -- 24.99); Pre obese (25.00 -- 29.99); Obese class I (30.00 -- 34.99); Obese class II (35.00 -- 39.99). Error bars represent the standard error of the mean. \*Association between BMI and qPCR ΔΔCt intensity signal, corrected for age, sex (DESIR), family (TwinsUK) and genotyping plate. \*\*Wilcoxon rank sum test.](emss-57335-f0003){#F3}

###### 

Summary information on subjects included in this study.

  Sample                                     Total                                   Male   Female   Median age   1^st^ -- 3^rd^ quartiles   Median BMI   1^st^ -- 3^rd^ quartiles
  ------------------------------------------ --------------------------------------- ------ -------- ------------ -------------------------- ------------ --------------------------
                                                                                                                                                          
  Swedish                                    342                                     98     244      37           (33 - 43)                  27.9         (22.6 - 36.5)
  TwinsUK                                    1,479[\*](#TFN1){ref-type="table-fn"}   \-     1,479    53           (45 - 60)                  26.0         (22.8 - 28.4)
  DESIR                                      2,137                                   942    1,195    52           (44 - 61)                  24.6         (22.2 - 26.6)
  AOB                                        563                                     160    403      35           (32 - 39)                  \-           \-
   Cases                                     205                                     39     166      36           (29 - 41)                  46.2         (42.5 - 51.3)
   Controls                                  358                                     121    237      35           (33 - 38)                  21.6         (20.3 - 22.4)
  SP2                                        658                                     237    421      46           (37 - 52)                  \-           \-
   Cases[\*\*](#TFN2){ref-type="table-fn"}   333                                     139    194      47           (40 - 54)                  27.1         (25.9 - 28.9)
   Controls                                  325                                     98     227      44           (34 - 51)                  18.4         (17.5 - 19.1)
  ABOS                                       468                                     122    346      43           (33 - 51)                  46.2         (41.7 - 52.3)

Consisting of 334 dizygotic and 193 monozygotic twin pairs and 425 singletons.

Including 136 obese (BMI ≥ 28 kg/m^2^) and 197 overweight (23 kg/m^2^ ≤ BMI \< 28 kg/m^2^) Singaporean Chinese subjects.

###### 

Association of relative copy-number in the amylase region with obesity and measures of adiposity. Copy-number estimates used in the association analyses for both the "Population samples" and the "Obesity case-control" samples were derived by qPCR.

  DNA Array-based CNV analysis^[\#](#TFN4){ref-type="table-fn"}^   *N*         Trait                                      Associated probe                                                                                               *P*                                                               
  ---------------------------------------------------------------- ----------- ------------------------------------------ ------------------ ------------------------------------------ ------------------------------------------------ -------------- -------------------------------------------------- ------------------------------------------------
  Swedish families                                                 342         BMI                                        cnvi0020639                                                                                                    3.86×10^−4^                                                       
  Swedish families                                                 331         Fat mass                                   cnvi0020639                                                                                                    3.11×10^−4^                                                       
  TwinsUK                                                          972         BMI                                        cnvi0022844                                                                                                    1.13×10^−3^                                                       
                                                                                                                                                                                                                                                                                                           
  **Population samples** [‡](#TFN3){ref-type="table-fn"}           ***N***     **BMI** [\*](#TFN5){ref-type="table-fn"}                      **Age** [\*](#TFN5){ref-type="table-fn"}   ***β (SE)*** ^[§](#TFN7){ref-type="table-fn"}^   ***P***                                                           
                                                                                                                                                                                                                                                                                                           
  TwinsUK                                                          1,479       26.0 (22.8-28.4)                                              53 (45-60)                                 −0.18 (0.05)                                     5.91×10^−4^                                                       
  DESIR                                                            2,137       24.6 (22.2-26.6)                                              52 (44-61)                                 −0.14 (0.03)                                     2.49×10^−7^                                                       
                                                                   ***N***                                                                                                              ***β (SE)*** ^[§](#TFN7){ref-type="table-fn"}^   ***P***                                                           ***Het P*** [\*\*](#TFN6){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                           
  Meta-analysis                                                    3,616                                                                                                                −0.15 (0.02)                                     6.93×10^−10^                                                      0.54
                                                                                                                                                                                                                                                                                                           
                                                                   **Cases**                                              **Controls**                                                                                                                                                                     
  **Obesity case-control** [‡](#TFN3){ref-type="table-fn"}         ***N***     **Age** [\*](#TFN5){ref-type="table-fn"}   ***N***            **Age** [\*](#TFN5){ref-type="table-fn"}   ***β (SE)*** ^[§](#TFN7){ref-type="table-fn"}^   ***P***        **OR (95%CI)** ^[§](#TFN7){ref-type="table-fn"}^   
                                                                                                                                                                                                                                                                                                           
  TwinsUK                                                          251         53 (47-60)                                 711                51 (44-59)                                 −0.26 (0.09)                                     3.61×10^−3^    1.30 (1.08-1.55)                                   
  DESIR                                                            137         55 (47-64)                                 1267               51 (42-59)                                 −0.16 (0.04)                                     7.47×10^−5^    1.18 (1.09-1.27)                                   
  AOB                                                              205         36 (29-41)                                 358                35 (33-38)                                 −0.17 (0.04)                                     4.44×10^−5^    1.19 (1.10-1.29)                                   
  SP2                                                              136         47 (37-54)                                 325                44 (34-51)                                 −0.15 (0.05)                                     3.73×10^−3^    1.17 (1.05-1.29)                                   
                                                                   ***N***                                                ***N***                                                       ***β (SE)*** ^[§](#TFN7){ref-type="table-fn"}^   ***P***        **OR (95%CI)** ^[§](#TFN7){ref-type="table-fn"}^   ***Het P*** [\*\*](#TFN6){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                           
  Meta-analysis[\*\*\*](#TFN8){ref-type="table-fn"}                593                                                    2,336                                                         −0.18 (0.03)                                     1.46×10^−10^   1.19 (1.13-1.26)                                   0.62

The listed numbers of samples are those which passed quality control and were used in the association analyses.

Obesity case-control analyses in TwinsUK and DESIR were conducted using a subset (subjects with BMI \< 25kg/m^2^ and those with BMI ≥ 30kg/m^2^) of those subjects included in the quantitative trait analysis in the population samples category.

"DNA Array-based" denotes signal intensity data from Illumina SNP genotyping arrays

median (1st, 3rd quartiles)

Heterogeneity *P*-value

Estimates calculated using integer *AMY1* copy-numbers inferred from the underlying continuous distribution.

Obesity case-control meta-analysis was limited to European samples.
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